PMID: 7089490Mar 1, 1982Paper

Soluble cytostatic factor(s) released from human monocytes. I. Production and effect on normal and transformed human target cells

Scandinavian Journal of Immunology
J Hammestrøm

Abstract

Human monocytes activated with lymphokines after 3-7 days of in vitro maturation released stable cytostatic factor(s) (CF), as determined by reduction of [methyl-3H]thymidine incorporation and cell counts in target cell cultures. Lipopolysaccharide from Escherichia coli slightly enhanced the release of CF. The CF release was greatest at an intermediate stage of the in vitro monocyte maturation to large, macrophage-like cells. Three transformed human cell lines (NHIK 3025, K-562, and U-20S) and normal skin fibroblasts were consistently inhibited by CF. Normal human mesothelial cells were variably affected, while normal human lymphocytes proliferating in response to allogeneic cells in mixed lymphocyte culture were not inhibited. Further analysis of CF may disclose one of the mechanisms whereby human monocytes and macrophages inhibit growth of human tumour cells.

References

Jan 15, 1979·International Journal of Cancer. Journal International Du Cancer·A MantovaniR B Herberman
Oct 1, 1979·British Journal of Cancer·N Matthews
Jan 1, 1979·Scandinavian Journal of Immunology·J Hammerstrøm
Apr 1, 1979·The Journal of Experimental Medicine·C G Ragsdale, W P Arend
May 1, 1979·The Journal of Clinical Investigation·D J Cameron, W H Churchill
Dec 1, 1977·Cellular Immunology·I Gresser
Aug 1, 1978·British Journal of Cancer·N Matthews
Sep 15, 1967·International Journal of Cancer. Journal International Du Cancer·J Pontén, E Saksela

Citations

Oct 1, 1984·Scandinavian Journal of Immunology·J Nissen-Meyer, O Kildahl-Andersen
Feb 1, 1987·Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section C, Immunology·K S BjerveJ Nissen-Meyer
Jan 1, 1986·Acta Medica Scandinavica·C P Maury
Jun 1, 1984·Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section C, Immunology·O Kildahl-Andersen, S Seim
Jul 1, 1983·Scandinavian Journal of Immunology·B M EggenJ Hammerstrøm

Related Concepts

Neoplastic Cell Transformation
Immunologic Tumoricidal Activities
Cytolysins
Lymphocyte Activation
Macrophage
Monocytes

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.